Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Exec Edge

03-27

Visit Exec Edge Research for Full Report

By Exec Edge Research

Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.

As we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.

Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.

Visit Exec Edge Research for Full Report

Executives-Edge.com

Rayk@capmarketsmedia.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522359149"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522359149\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522359149?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 04:38","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2522359149","market":"nz","top_or_hot":-1,"title":"Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report","media":"Exec Edge","content":"<html><body><p><img height=\"533\" src=\"https://s.yimg.com/uu/api/res/1.2/ek1tHlISqTDMs3lK7cRFmg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a57d3f3d79919df2be9669d4d4605a19\" width=\"800\"/></p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>By Exec Edge Research</p>\n<p>Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.</p>\n<p>As we highlighted in our 66-page initiation report last week (<strong>download here</strong>), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.</p>\n<p>Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.</p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>Executives-Edge.com</p>\n<p>Rayk@capmarketsmedia.com</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Exec Edge</strong><span class=\"h-time small\">2025-03-27 04:38</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p><img height=\"533\" src=\"https://s.yimg.com/uu/api/res/1.2/ek1tHlISqTDMs3lK7cRFmg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a57d3f3d79919df2be9669d4d4605a19\" width=\"800\"/></p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>By Exec Edge Research</p>\n<p>Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.</p>\n<p>As we highlighted in our 66-page initiation report last week (<strong>download here</strong>), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.</p>\n<p>Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.</p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>Executives-Edge.com</p>\n<p>Rayk@capmarketsmedia.com</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html\">Exec Edge</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html","article_id":"2522359149","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522359149","pubTimestamp":1743021535,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Climb Bio, Inc.  reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.As we highlighted in our 66-page initiation report last week , CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy , systemic lupus erythematosus and lupus nephritis , and immune thrombocytopenia . The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ITP":"IT科技包装","CLYM":"CLIMB BIO INC","BK4199":"纸制品"},"translate_title":"Climb Bio注入现金，准备在25季度更新报告中实现更多里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9,"ITP":1},"content_text":"Enter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nBy Exec Edge Research\nClimb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.\nAs we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.\nImportantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEnter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nExecutives-Edge.com\nRayk@capmarketsmedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}